Champions Oncology Inc
NASDAQ:CSBR

Watchlist Manager
Champions Oncology Inc Logo
Champions Oncology Inc
NASDAQ:CSBR
Watchlist
Price: 7.505 USD -0.6% Market Closed
Market Cap: 102m USD
Have any thoughts about
Champions Oncology Inc?
Write Note

Champions Oncology Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Champions Oncology Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Champions Oncology Inc
NASDAQ:CSBR
Cash & Cash Equivalents
$2.8m
CAGR 3-Years
-17%
CAGR 5-Years
0%
CAGR 10-Years
17%
Thermo Fisher Scientific Inc
NYSE:TMO
Cash & Cash Equivalents
$4.6B
CAGR 3-Years
-27%
CAGR 5-Years
30%
CAGR 10-Years
24%
Danaher Corp
NYSE:DHR
Cash & Cash Equivalents
$2.6B
CAGR 3-Years
1%
CAGR 5-Years
-29%
CAGR 10-Years
-4%
Mettler-Toledo International Inc
NYSE:MTD
Cash & Cash Equivalents
$71.6m
CAGR 3-Years
-27%
CAGR 5-Years
-10%
CAGR 10-Years
-6%
Agilent Technologies Inc
NYSE:A
Cash & Cash Equivalents
$1.3B
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
-5%
IQVIA Holdings Inc
NYSE:IQV
Cash & Cash Equivalents
$1.6B
CAGR 3-Years
2%
CAGR 5-Years
13%
CAGR 10-Years
9%
No Stocks Found

Champions Oncology Inc
Glance View

Market Cap
102.8m USD
Industry
Life Sciences Tools & Services

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.

CSBR Intrinsic Value
7.1 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Champions Oncology Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.8m USD

Based on the financial report for Oct 31, 2024, Champions Oncology Inc's Cash & Cash Equivalents amounts to 2.8m USD.

What is Champions Oncology Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
17%

Over the last year, the Cash & Cash Equivalents growth was -50%. The average annual Cash & Cash Equivalents growth rates for Champions Oncology Inc have been -17% over the past three years , and 17% over the past ten years .

Back to Top